닫기

홈>Pipeline

Pipeline

Ophthalmology

Novelty Nobility develops NN2101, a therapeutic monoclonal antibody inhibiting SCF/c-kit pathway, for the treatment of wet AMD and DR/DME. NN2101, based on differentiated mechanism of action from anti-VEGFs, is expected to mitigate the potential risk of every anti-VEGF drug, including cardiovascular defects and to show superior efficacy and dosing interval to aflibercept(Eylea).

NN2101Potential Indications: wet AMD, DR/DME

Research

Preclinical

Phase I/II

Phase III

Oncology

Novelty Nobility researches c-kit antibody-drug conjugate for oncology. Activating mutation of c-kit is observed on various cancer types with a frequency ranging from 20 to 85 percent, including GIST and Leukemia, and is well known as the primary driver of resistance to imatinib(Gleevec). NN3201 is designed using a commercial linker and NN3202 adopts a proprietary linker technology.

NN3201/ NN3202Potential Indications: GIST, Leukemia, GBM

Research

Preclinical

Phase I/II

Phase III

Rare Disease

NN2901 is a c-KIT antagonist antibody for treating Retinopathy of Prematurity(ROP). ROP is a potentially blinding eye disorder affecting premature infants, for their entire life when treatment fails. Invasive surgeries are standard, and anti-VEGF therapies will be indicated shortly. Given the safety and avascular normalization of SCF/c-KIT, however, we believe NN2901 could provide a superior therapeutic option.

NN2901Potential Indications: ROP

Research

Preclinical

Phase I/II

Phase III

Novelty Nobility eyes on Mastocytosis, the rare disease of which up to 90% of c-kit activating mutation is reported. Imatinib is a standard, but some types of c-KIT mutation drive resistance. NN3901 is a c-kit antibody-drug conjugate.

NN3901Potential Indications : Mastocytosis

Research

Preclinical

Phase I/II

Phase III